RCM
ITCI

RA Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

RA Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-314,349
Closed -$12.6M – 47
2015
Q3 		$12.6M Buy
+314,349
New +$10.3M 1.81% 20

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RA Capital Management's ITCI Position: Q4 2015 in Review

RA Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2015, closing a stake of 314,349 shares — an estimated $12.6M sold.

RA Capital Management first reported a position in ITCI in Q3 2015 and held it in 1 quarter. The position peaked at $12.6M in Q3 2015. 132 funds tracked by Wall St. Rank hold ITCI as of Q4 2015.

  • RA Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2015 after selling out during the quarter.
  • RA Capital Management sold 314,349 Intra-Cellular Therapies Inc. shares in Q4 2015, an estimated $12.6M.
  • RA Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 1 quarter.
  • RA Capital Management's Intra-Cellular Therapies Inc. position peaked at $12.6M in Q3 2015.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2015.

Based on RA Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.